Efficacy of imatinib on advanced and refractory desmoid tumors: a retrospective study

Basit Öğe Kaydı
dc.authoridOrçun Can / 0000-0002-9400-105X
dc.authorscopusidOrçun Can / 57204774164en_US
dc.authorwosidOrçun Can / AGX-9627-2022
dc.contributor.authorAtçı, Muhammed Mustafa
dc.contributor.authorCan, Orçun
dc.contributor.authorSeçmeler, Saban
dc.contributor.authorSakin, Abdullah
dc.contributor.authorAy, Seval
dc.contributor.authorCihan, Sener
dc.contributor.authorSelvi, Oğuzhan
dc.contributor.authorGeredeli, Cağlayan
dc.date.accessioned2022-11-08T12:49:32Z
dc.date.available2022-11-08T12:49:32Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Hastaneen_US
dc.description.abstractABS TRACT Objective: Our study aimed to analyze imatinib’s efficacy, tolerability, and safety in treating naive patients with unresectable and progressive desmoid tumors. Material and Methods: The data of patients who were ?18 years old diagnosed with desmoid tumors treated with imatinib were evaluated retrospectively regarding their demographic features, comorbidities, disease stage, pathological features of the tumor, response rates and progression-free survival (PFS). Results: In our study, 36 patients with advanced desmoid tumors receiving ima-tinib with a median age of 28 [interquartile range (IQR): 21-40] years-old of whom 58.3% were female were included. The patient’s complete response, partial response, stable disease, and progressive disease with imatinib 800 mg/day were 13.9%, 44.4%, 27.7%, and 13.9%, respec-tively. The Grade-3 adverse events, including neutropenia (n=3, 8.3%) and rash (n=3, 8.3%), were relieved after dose reduction. The median PFS was 29 months (95% confidence interval, 16-42 months) with imatinib, and only 3 (8.3%) patients were exitus due to disease progression during the follow-up (median: 43 months, IQR: 24.3-70.8). Conclusion: Our study provided clinical evidence of the efficacy and safety of imatinib in patients with desmoid tumors with real-world experience. However, appropriately designed randomized-controlled clinical trials are needed to explore the effectiveness of imatinib in desmoid tumors to provide an alternative management approach.en_US
dc.identifier.citationAtci, M. M., Can, O., Seçmeler, Ş., Sakin, A., Ay, S., Cihan, Ş., . . . Geredeli, Ç. (2022). Efficacy of imatinib on advanced and refractory desmoid tumors: A retrospective study. Journal of Oncological Science, 8(2), 63-68. doi:10.37047/jos.2021-87391en_US
dc.identifier.doi10.37047/jos.2021-87391en_US
dc.identifier.endpage68en_US
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85136821708en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage63en_US
dc.identifier.trdizinid1123591en_US
dc.identifier.urihttps://doi.org/10.37047/jos.2021-87391
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3254
dc.identifier.volume8en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorCan, Orçun
dc.language.isoenen_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofJournal of Oncological Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDesmoid Tumorsen_US
dc.subjectEfficacyen_US
dc.subjectImatiniben_US
dc.titleEfficacy of imatinib on advanced and refractory desmoid tumors: a retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
529849664221006 (1).pdf
Boyut:
423.94 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu